The U.S. Food and Drug Administration on Friday approved a new drug for the treatment of kidney cancer.

Pfizer’s Inlyta will be used to treat advanced kidney cancer patients who haven’t responded to other drugs. Its approval was unanimously supported by an advisory committee last month. The pill works by blocking proteins called kinases, which can spur tumor growth.

Inlyta joins a crowed space – seven drugs have been approved for the treatment of metastatic or advanced kidney cell cancer since 2005.